|
11th International AIDS ConferenceVancouver, British Columbia — July 7-12, 1996 |
Table of Contents - Late-BreakersMo = Monday, Tu = Tuesday, We = Wednesday, Th = Thursday, Lb = Late-Breaker Cite as: Int Conf AIDS. 1996 Jul 7-12;11:Abstract No. xx |
| Lb.D.6069 | Sexual behavior change due to HIV/AIDS: results from population based surveys conducted in five districts of Uganda. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. LB.D.6069) Opio AA, Musinguzi J, Asiimwe-Okiror G, Byabamazima C, Turyaguma P, Madraa E, Nsubuga P, Kawesa D; STD/ACP Ministry of Health, Entebbe, Uganda. Fax: 256-42-20608. To provide baseline data for evaluation of STD/AIDS Control Programme. Methods: From October 1995 to November 1995, population-based studies were conducted in 5 districts of Uganda . Subjects were selected through a multistage sampling technique. First, 50 clusters were randomly selected from each study dom |
| Lb.D.6068 | Participatory approach in the campaign against AIDS/STDs in schools. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. LB.D.6068) Goungou ES, Dikewu A, Clavreul J, Grunitzky-Bekele M, Ouyi W; Lome, Togo. To bring students to be actively involved in the prevention of STDs/AIDS and to adopt responsible behaviors. To provide for the needs of information and training of students in the domains dealing with affection, sex and STDs/AIDS. Method: Training of 578 Inspectors, Advisers and Teachers of the 300 Colleges |
| Lb.D.6067 | Perception variations in AIDS clinical trial participants of differing demographic backgrounds. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. LB.D.6067) Maimon G, Giordano MF, Grimes-Gruczka T; NY Hospital-Cornell Medical Centre, Cornell Clinical Trials Unit, New York, NY. Fax: (212) 746-8415. E-mail: gm19@cornell.edu. As the population of AIDS clinical trial participants diversifies, it becomes important to understand the motivations and experiences of the various subgroups of patients. A survey study was conducted on patient sentiment towards clinical studies as well as the variability in these opinions that could be att |
| Lb.D.6066 | AIDS outreach program targeting single mothers who are office secretaries in and around Nairobi. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. LB.D.6066) Kamau MM, Bwayo JJ, Ngugi EN, Ndinya-Achola JO; Department of Human Pathology, University of Nairobi, Nairobi, Kenya. Single mothers in Kenya are economically unstable. The men responsible for the pregnancy disappear with no guilt of what they have done. This makes the women therefore increasingly at higher risk than men who provide money and goods in exchange for sex. |
| Lb.D.6064 | Prevention--international best practice highlights. Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. LB.D.6064) de Burger R; Canadian Public Health Association, Ottawa, ON, Canada. Fax: (613) 725-9826. E-mail: rdeburger@cpha.ca. HIV Prevention Works , an official satellite of the XI International Conference on AIDS takes a unique approach to prevention by exploring and uniting a broad spectrum of issues including underlying social conditions which make various groups vulnerable to HIV disease. It focuses on behavioral, social and economic cha |
| Lb.C.6063 | Feasibility of isoniazid preventive therapy (IPT) in HIV-infected persons, Chiangmai, Thailand. (First year report). Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. LB.C.6063) Natpratan C, Akrasewi P, Kongsin S, Prapanwong A; Office of Communicable Disease Control Region 10, Chiang-Mai, Thailand. Fax: 66-53-271020. TB is a common opportunistic infection among HIV/AIDS patients in northern Thailand . The seroprevalence of HIV in TB patients increased from 5.2% in 1989 to 40% in 1995. HIV-associated TB has high morbidity and mortality. |
| Lb.C.6062 | Improved STD treatment significantly reduces prevalence of syphilis and symptomatic urethritis in rural Tanzania. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. LB.C. 6062) Mwijarubi E, Grosskurth H, Mosha F, Mayaud P, Mugeye K, Todd J, Cornelissen J, West B, Gavyole A, Hayes R, Mabey; Tropical Health Epidemiology Unit, London School of Hygiene & Tropical Medicine, London, England. Fax: 44-171-436-4230. E-mail: ethehgro@lshtm.ac.uk. To measure the impact of improved STD management, using the syndromic approach at the primary health care level, on STD prevalences in Mwanza Region, Tanzania . The impact on HIV incidence (a 42% reduction) has been reported previously, but only preliminary data on STD impact have been published. Methods: Co |
| Lb.C.6061 | Determinant of Ethiopian rural schools involvement in AIDS prevention: schools knowledge about AIDS. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. LB.C.6061) Azeze B, Yohannes G, Alemu S, Kidan GK, Isheak A, Endeshaw S; Gondar College of Medical Sciences, Ethiopia. Fax: 11-14-79. This study explores the determinant factor, AIDS knowledge, for rural high school involvement in AIDS prevention activities at a rural community where mass medias are scarce. |
| Lb.C.6060 | A training long-term effects addressed to health care personnel working with young gays and bisexuals. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. LB.C.6060) Vassal A, Otis J, Chouinard N, Pilote F; Montreal, Quebec, Canada. Fax: (514) 288-0606. To evaluate long-term effects of a two phases training, addressed to personnel from health and social services as well as community network, working eventually, with young gays and bisexuals. |
| Lb.C.6059 | Using oral fluid specimens to extend HIV antibody testing to difficult to reach urban and rural populations. Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. LB.C.6059) Judson F, Breese P, Winters R, Columbus C, Santistevan C, George JR; Epitope, Inc., Beaverton, OR. Fax: (503) 643-2781. Testing for HIV infection among some at risk populations is limited by resistance to the invasive nature of the procedure and by the reach of traditional counseling and testing programs. |
| Lb.C.6058 | HIV-testing on the initiative of the patient in general practice in eight European countries (1990-1994) ("Europe against AIDS") Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. LB.C.6058) Van Renterghem H, Van Casteren V, Szecsenyi J, Bartelds A, Cloetta J, Falcao I, Massari V, Maurice S, Vega AT, Wigersma L, Stroobant A; Institute for Hygiene and Epidemiology, Brussels, Belgium. Fax: 32-2-642-5410. E-mail: andre.stroobant@epinov.ihe.be. Objective: To describe and explain regional/national differences and temporal changes in the demand for HIV-test by patients in general practice in eight European countries. Methods: From 1990 to 1994, 9 sentinel networks (SNs) of general practitioners (GPs) from 7 European countries-- Belgium (national SN), |
| Lb.C.6056 | Sydney blood bank cohort: (SBBC) additional long-term non-progressor with HIV (LTNP) identified; immunological update on SBBC 12-15 years post infection. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. LB.C.6056) Learmont J, Rhodes D, Soloman A, Wood J, McIntyre L, Dyer W, Geczy A, Deacon N, Sullivan J; NSW Blood Transfusion Service, Sydney, NSW, Australia. Fax: 612/229-4479. Objectives: To identify the recipient of a unit donated in 1981 by the single donor in the SBBC. To monitor the immunological and surrogate markers for HIV progression of the SBBC. These include CD4, CD8, CD4:CD8 ratio, CD3 and total lymphocyte counts and p24 available data. Methods: The destination of a unit donated i |
| Lb.C.6055 | Factors related to the progression of HIV-infection in women in Britain and Ireland. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. LB.C.6055) Griffioen A; University College London Medical School, London, WUE. Fax: 0171-388 4179. E-mail: agriffioen@qum.ucl.acuv. Objectives: To describe the factors related to progression of HIV disease in a cohort of HIV positive women. Methods: Cohort study of HIV positive women recruited from 15 Genito-urinary Medicine/HIV clinics in Britain and Ireland between June 1992 and August 1995. Cox proportional hazard models have been used to invest |
| Lb.C.6054 | Impact of pregnancy on maternal AIDS (a prospective study). Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. LB.C.6054) Kumar RM, Khuranna A, Uduman S; Faculty of Medicine and Health Sciences, United Arab Emirates University, Alain, UAE. Fax: (9713) 657134. Aim: To assess the impact of pregnancy on maternal AIDS among tribal women from India . Design: At Government hospital in Manipur, 71 women with AIDS (CDC III/IV) were identified and prospectively studied from December 1992 to January 1996. Of these 71, 32 were pregnant (Group A) and 39 non-pregnant (Group B). Both gro |
| Lb.C.6053 | HIV-1 endemicity and the risk of seroconversion among heterosexual men in the U.S. army. Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. LB.C.6053) Levin LI, Renzullo PO, Garner R, Lasley-Bibbs V, McNeil J; Preventive Medicine, WRAIR, Rockville, MD. Fax: (301) 294-1898. E-mail: prenzull@hiv.hjf.org. To evaluate whether female sex partners from high HIV-1 prevalence areas increase the risk of seroconversion among heterosexual men in the U.S. army. Methods: Cases were 70 men in the Army who seroconverted between July 1986 and December 1991 and who reported only having sex with women. Controls were active- |
| Lb.C.6052 | Risk factors for HIV infection in a sample of out-of-treatment injection drug users in California. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. LB.C.6052) Mikanda J, Ruiz J, Flynn N, Walters J, Sun R; California Department of Health Services, Office of AIDS, Sacramento, CA. Fax: (916) 327-3252. E-mail: jmikanda@hwl.cahwnet.gov. Objective: To examine changes of risk behaviours and its determinants as well as risk factors for HIV infection among Out-of-Treatment Injection Drug Users (OTIDUs) with a particular attention to incarceration status and its risk patterns. Methods: In 1994 a multisite cross-sectional study was conducted among 1550 OTID |
| Lb.C.6050 | Saquinavir in the treatment of HIV infection: patterns of use in the French Compassionate use programme, 1996. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. LB.C.6050) Rousselle B, Dohin E, Pichon F, Andriamanamihaja M, Goehrs JM; Produits Roche, Medical Department, Neuilly-sur-Seine, France. Fax: 33 1 46.40.53.31. Objective: To describe patterns of use for the Roche HIV Protease Inhibitor (PI), Saquinavir during the French Compassionate use programme (see below for clarification of ATU) since February 1996. Methods: Saquinavir (SQV) was the first HIV PI to be made available to the French AIDS patients (pts). |
| Lb.C.6049 | Molecular epidemiology of HIV-1 in Venezuela. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. LB.C.6049) Quinones-Mateu ME, Pacheco M, Acevedo N, Domingo E; Centro de Biologia Molecular "Severo Ochoa," Madrid, Spain. Fax: 34-1-397-4799. E-mail: mquinone@mvax.cbm.uam.es. Objective: To analyze two groups of HIV-1 isolates from Venezuela (1991 and 1994/95) by HMA subtyping and to characterize sequence evolution for three different genomic regions in recent years. Methods: Twenty-eight blood samples from HIV-1 positive Venezuelan patients were obtained in two periods: March-Oct. 91 and Au |
| Lb.B.6048 | A pharmacoeconomic analysis of Kaposi's sarcoma patients based on a clinical trial of ABV vs. DaunoXome. Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. LB.B.6048) Savage GE, Gable C, Motte K, Dixon C, Becker R; Health Economics State and Federal Associated, Inc., Alexandria, VA. Fax: (703) 683-2239. Objective: A pharmacoeconomic analysis based on clinical trial data comparing standard treatment Adriamycin, Bleomycin, and Vincristine (ABV) with a new single product, liposomal daunorubicin ( DaunoXome ), for the treatment of advanced Kaposi s sarcoma. Methods: The analysis is a cost minimization model assuming equal |
| Lb.B.6047 | The economic impact of treatment of HIV-positive women and their newborns with zidovudine: implications for HIV screening. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. LB.B.6047) Mauskopf J, Paul J, White A, Tilson H; Glaxo Wellcome Inc., Research Triangle Park, NC. Fax: (919) 483-3096. E-mail: JAM18448@GLAXO.COM. Objectives: To estimate the economic and health impacts of (1) treating pregnant women who are human immunodeficiency virus (HIV)-positive with zidovudine and (2) voluntary HIV screening programs for pregnant women. Methods: Health care costs and reduced cases of pediatric HIV infection were estimated. Health care cost |
| Lb.B.6046 | Quality of life consequences of adding ritonavir to current antiviral therapy for advanced HIV patients. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. LB.B.6046) Nabulsi AA, Revicki D, Conway D, Maurath C, Mills R, Leonard J; Abbott Park, IL. Fax: (847) 937-1992. E-mail: Azmi.Nabulsi@Abbott.com. A randomized, double-blind, multi-national clinical trial of a protease inhibitor, ritonavir , plus existing treatment versus medical treatment alone was performed on HIV-infected patients with CD4 counts of less than or equal to 100 cells/L. Patients in both treatment groups were allowed to maintain existing prophylac |
| Lb.B.6045 | The use of EuroQol preference scale in AIDS. Results from two clinical trials. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. LB.B.6045) Nabulsi AA, Revicki D, Conway D, Maurath C, Leonard J; Abbott Park, IL. Fax: (847) 937-1992. E-mail: Azmi.Nabulsi@Abbott.com. The EuroQol is a multidimensional preference scale with a total summary score on global quality of life. The EuroQol is a generic instrument that is self-administered. It is comprised of five dimensions of health status (mobility, self care, pain, role function, anxiety and depression). The EuroQol questionnaire was ad |
| Lb.B.6044 | Results of paired saliva-serum HIV antibody testing in high risk Cambodian population. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. LB.B.6044) Szipola G, Hor Bun L, Huszar A; HQs of Budapest Police, Health Department, Budapest, Hungary. Fax: 36-1-32601878. E-mail: 100324.1321@compu-serve.com. Objectives: Identifying the frequency of HIV infections in a surveillance programme of high-risk and low-risk sentinel groups in Koh Kong province. To evaluate saliva HIV antibody testing as a non-invasive and cost-effective alternative to serum. Methods: Paired samples of saliva and serum were collected from 271 subje |
| Lb.B.6043 | Home care, a challenge to community based organizations in Kampala District-Uganda. Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. LB.B.6043) Odongo-Aginya D, Madraa E, Eriki M; STD/AIDS Control Programme, Entebbe, Uganda. Fax: 256-42-20608. A person with AIDS can register with more than one organization for treatment and material support which are often inadequate. Project: Community Based/Home Care Programme was initiated by various Non-Governmental Organizations in Kampala District as early as 1987. Strategies of Home Care Programme include medic |
| Lb.B.6042 | Multidisciplinary hospital based HIV consultation service: a model for states with rural communities. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. LB.B.6042) Smith R, Putnam ST, Luce C, Perkins P, Anderson K; AIDS Consultation Service, Maine Medical Center, Portland, ME. Fax: (207) 871-6116. E-mail: smithr.data@office.mmc.org. In the second decade of the AIDS epidemic, an increasing proportion of cases are reported from rural areas. In Maine, the percentage of AIDS cases reported from non-metropolitan areas increased from 30% to 58% between 1986 to 1994. Provision of state-of-the-art care for persons with HIV living in rural areas is |
| Lb.B.6041 | Assessment of single- and multiple-dose interactions between ritonavir and saquinavir. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. LB.B.6041) Hsu A, Granneman GR, Sun E, Chen P, El-Shourbagy T, Locke C, Baroldi P, Carothers L, Cao G, Qian J, Pizzuti D, Stewart F, Leonard J; Abbott Laboratories, Abbott Park, IL. Fax: (847) 938-5193. E-mail: Ann.Hsu@abbott.com. Study Design: Two interaction studies have been conducted in healthy, non-HIV female and male volunteers using Norvir capsules and Invirase capsules under nonfasting conditions. The single-dose study involved 6 dose groups utilizing a crossover design and the 2-week multiple-dose study invol |
| Lb.B.6040 | Clinical trial of Buxux Sempervirens L. Preparation (SPV 30) in asymptomatic HIV infected patients. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. LB.B.6040) Vandermander J, Durant J, Chantre P, Dellamonica P; Arkopharma, Carros, France. Fax: 33.93.29.11.62. Objective: To assess the efficacy and safety of SPV 30 (a boxwood preparation listed in the Pharmacopea) in asymptomatic patients (group II-III, CDC 1987) with CD4+ cell count between 250 and 500/mm(3) at day 1. Methods: 150 asymptomatic patients have been followed for 12 to 18 months during a phase II-III, multicenter |
| Lb.B.6039 | Development of an anti-HIV oligodeoxynucleotide gp12A: inhibition of multiple HIV strains and in vivo pharmacokinetic properties. Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. LB.B.6039) Anazodo MI, Liu C, Powers C, Duta E, Friesen A, Wainberg M, Wright J; Manitoba Institute of Cell Biology, Winnipeg, MB, Canada. Fax: (204) 787-2190. Objective: Preclinical and clinical development of an antisense oligodeoxynucleotide drug against HIV and its application to the treatment of HIV/AIDS disease. Methods: A partially thiolated antisense oligodeoxynucleotide sequence (GP12A) was synthesized that targets a conserved region of the HIV-1 gag sequence. Initia |
| Lb.B.6038 | Rational interleukin 2 therapy for HIV+ individuals: daily low doses enhance immune function without toxicity. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. LB.B.6038) Smith KA, Jacobson L, Pilaro F; New York Hospital-Cornell University Medical College, New York, NY. Fax: (212) 746-8167. E-mail: kasmith@mail.med.cornell.edu. Objectives: When administered in high doses to HIV+ individuals, interleukin 2 ( IL-2 ) causes extreme toxicity and markedly increases plasma HIV levels. Integration of the information from the structure-activity relationships of the IL-2 receptor interaction, the cellular distribution of the different classes of IL-2 |
| Lb.B.6037 | HIV-specific transfer factor. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. LB.B.6037) Chiodo F, Raise F, Gritti F, Pizza G, Fudenberg HH, DeVinci C, Viza D; Neuro ImmunoTherapeutics Research Foundation, Spartanburg, SC. Fax: (803) 591-0622. E-mail: compuserve ID 103765, 1153. Rationale: Specific transfer factor (TF) is known to be efficacious in treating or preventing viral infections. Methods: HIV-specific TF was made from immunized BALB/c mice, and replicated in tissue culture and encapsulated for oral administration. Results: 20 ARC patients, treated with TF and zidovudine (ZDV) for more |
| Lb.B.6036 | Effects of the aqueous extract of snail Achatina fulica Bowdich on HIV-infected individuals. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. LB.B.6036) Young KC, Hee JL, Eun SK, Won IO; Department of Microbiology, College of Medicine, University of Ulsan, Seoul, Korea. Fax: 82 (02) 224-4283. Objective: To determine the effects of snail Achatina fulica Bowdich extract (AFE) in HIV-infected individuals (HIV+). The anti-HIV effect of the purified components from Achatina fulica in vitro was already confirmed by Ashok D. Patil et al (J Med Chem 36:4131-38, 1993). Methods: Thirty HIV+ were treated with AFE (Chu |
| Lb.B.6034 | Prime-boost protocols for vaccination against HIV. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. LB.B.6034) Excler JL, Duliege AM, Clements ML, Salmon D, McNamara J, Fast P, Meignier B, Klein M, Plotkin SA; Pasteur Merieux Serums & Vaccins, France. Fax: 33.1.47.95.80.00. Vaccination against HIV should evoke both neutralizing antibodies and cellular immune responses. No single antigen has yet demonstrated the ability to produce both types of responses. Nevertheless, glycoproteins administered with good adjuvants have been adept at inducing neutralizing antibodies against laboratory stra |
| Lb.B.6033 | Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC). Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. LB.B.6033) Lalezari J, Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo MP; Mt. Zion Hospital of UCSF, San Francisco, CA. Fax: (415) 476-3622. E-mail: miklos.salgo@roche.com. Objective: To compare the safety, tolerability and efficacy of SQV plus ddC , compared to ddC or SQV alone. Methods: In this double-blind, multicentre, phase II/III study, HIV infected patients with a CD4 lymphocyte count of 50-300 cells/mm(3), and greater than or equal to 16 weeks of prior ZDV therapy, were randomized |
| Lb.B.6032 | Epivir (3TC) expanded access program - North American safety experience. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. LB.B.6032) Conant M, Self P, Liao E, Cocchetto D, Rubin M; Conant Medical Group, San Francisco, CA. Fax: (415) 661-6275. Objectives: To establish an Expanded Access Program to provide access to and obtain safety data on Epivir therapy. Methods: Adult and pediatric patients in the U.S. and Canada with progressive, symptomatic HIV disease who had a baseline CD4 cell count less than or equal to 300 cells/mm(3) and were refrac |
| Lb.B.6031 | Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. LB.B.6031) Markowitz M, Cao Y, Hurley A, O'Donovan R, Peterkin J, Anderson B, Smiley L, Keller A, Johnson P, Johnson D, Ho DD; The Aaron Diamond AIDS Research Center, New York, NY. Fax: (212) 725-1126. E-mail: marty@adarc.nyu.edu. Triple therapy with 2 nucleoside RT inhibitors and a potent protease inhibitor may erect an antiviral barrier such that durable suppression of measurable viral replication occurs. This, in turn, should result in long-term immunologic benefit. To test this hypothesis, 12 antiretroviral-naive HIV-infected subjects with a |
| Lb.B.6030 | Treatment of advanced HIV infection with ritonavir plus saquinavir. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. LB.B.6030) Hirschel BJ, Rutschmann O, Fathi M, Gabriel V, Mendoula A, von Overbeck I, Iten A; Divisions of Infectious Diseases, University Hospitals, Geneva, Switzerland. Objectives: To conduct a pilot study of the rit/saq combination in advanced HIV infection. Patients: 7 patients with median CD4 count of 10, all with previous AIDS-defining conditions, 5 with active disease (multiple drug-resistant TB with positive blood cultures, microsporidiosis , |
| Lb.B.6029 | Evaluation of HIV-activating UV doses in the skin exposed to phototherapy and photochemotherapy. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. LB.B.6029) Zmudzka BZ, Miller SA, Lightfoote MM, Jacobs ME, Beer JZ; FDA, Rockville, MD. Fax: (301) 594-6775. E-mail: bzz@fda.dr.gov. Objective: To evaluate the possibility of HIV activation in the skin treated with phototherapy (UVB therapy) or photochemotherapy (PUVA therapy). Methods: Using the data for HIV promoter activation in vitro, we computed UVB and PUVA doses that produce 50% of the maximal promoter activation (AD(50)). Then, using (a) lit |
| Lb.B.6028 | Gingival inflammatory exudate of AIDS patients contains macrophages in the productive phase of HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. LB.B.6028) Suzuki T, Tai H, Yoshie H, Jeannel D, Fournier S, Dupont B, de The G, Hara K; Niigata University School of Dentistry, Niigata, Japan. Fax: (+81) 25 223 3761. E-mail: takashi@dent.niigata-u.ac.jp. Objectives: To determine whether the p24-positive monocyte/macrophages detected in gingival inflammatory tissue exudate (AIDS 1996, in press) are HIV-infected population within which viral replication occurs. Design: Twenty-three CDC stage IV AIDS patients participated in the study. Leukocyte infiltrates in gingival cr |
| Lb.B.6027 | Microsporidiosis of the cornea in an AIDS patient. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. LB.B.6027) Stool E, Sawyer GS, Gathe J, Green M, Font R, Frazier R, Schrader S; Park Plaza Hospital, Houston, TX. Fax: (713) 524-0018. Objective: To show an unusual corneal infection in an AIDS patient that mimics keratitis sicca and its treatment. Methods: Retrospective chart review of a patient with corneal infection who was followed prospectively by the authors. Results: M.S. is a 37 year old AIDS patient who presented 4/95 with severe pain in both |
| Lb.B.6026 | Randomized comparative trial of DOXIL vs. Bleomycin and Vincristine in the treatment of AIDS-Related KS. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. LB.B.6026) Stewart S, Jablonowski H, Goebel FD, L'Age M, Spittle M, Luthy R; Oncology Department, St. Mary's Hospital, London, UK. Fax: 44-171-725-1840. E-mail: simon@dukav.demon.co.uk. 241 patients with HIV related Kaposi s Sarcoma (KS) were randomized to receive six 3-weekly cycles of either BV-Bleomycin, 15 mg/m(2) and Vincristine 2 mgs (120 patients)or DOXIL-20 mg/m(2) (121 patients). Both groups were well matched for prognostic factors: according to ACTG criteria, Poor Risks KS was seen in 57 ( |
| Lb.B.6025 | Comparison of two doses of clarithromycin in a randomized trial of four 3-drug regimens for treatment of disseminated Mycobacterium avium complex disease in AIDS: excess mortality associated with high-dose clarithromycin. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. LB.B.6025) Cohen DL, Fisher E, Franchino B, Hodges J, Chestnut J, Child C, Gilbert C, El-Sadr W, Hafner R, Ropka M, Heifets L, Clotfelter J, Munroe D, Caldwell R, Canady K, Horsburgh C; Denver CPCRA, Denver, CO. Fax: (303) 436-7211. E-mail: cohnd@essex.uchsc.edu. Objective: To compare the safety and efficacy of four regimens in treatment (Rx) of disseminated Mycobacterium avium complex disease (DMAC) in patients (pts) with AIDS. Methods: From 3/95 to 2/96, patients with AIDS and DMAC or presumptive DMAC were randomized to receive one of four 3-drug regimens in a factorial desig |
| Lb.B.6024 | HIV-1 RNA quantification by NASBA in matched plasma and cervico-vaginal lavage in HIV seropositive women. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. LB.B.6024) Caliendo A, Cu-Uvin S, Costello S, Murphy D, Mayer K, Flanigan T, Carpenter C; Brown University AIDS Program, Miriam Hospital, Providence, RI. Fax: (401) 331-8501. Objective: To quantitate HIV-1 RNA levels in matched plasma and cervico-vaginal lavage (CVL) specimens from HIV-1 positive women. Methods: Matched plasma and CVL specimens were collected from 22 HIV-1 positive women. HIV-1 RNA was quantitated using the NASBA assay (Organon Teknika). One ml of plasma or CVL was added to |
| Lb.B.6023 | Characteristics and identification of early HIV seroconverters. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. LB.B.6023) Celum C, Buchbinder S, Donnell D, Douglas J, Mayer K, Marmor M, Koblin B, Flores J, Self S, Sheppard HW; Pacific Medical Centre, Seattle, WA. Fax: (206) 621-4582. E-mail: ccelum@u.washington.edu. Objectives: Pathogenesis and treatment studies on acute HIV infection usually enroll symptomatic seroconverters. To evaluate whether referral-based populations may differ from prospectively-identified unselected seroconverters, we compared seroconverters who sought medical care to those who did not seek care by viral l |
| Lb.B.6022 | A pilot study to evaluate the efficacy of zidovudine (ZDV) versus placebo in primary HIV infection (DATRI 002): a preliminary analysis. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. LB.B.6022) Holodniy M, Niu M, Bethel J, Standiford H, Schnittman S; VA Medical Center, Palo Alto, CA. Fax: (415) 858-3978. E-mail: hf.myh@forsythe.stanford.edu. Objectives: To assess the role of ZDV initiated during primary HIV infection (PHI), prior to the establishment of chronic infection, and to provide insight into the pathogenesis of PHI. Methods: patients presenting with symptoms were screened for evidence of acute HIV infection; patients with p24 antigenemia and negati |
| Lb.B.6021 | Rapid viral load decrease in primary infection associated with aggressive therapy. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. LB.B.6021) Workman C, Downie J, Sutherland D, Smith DE, Dyer W, Shen J, Sullivan J; Primary Care Physician, New South Wales, Australia. Fax: 61-2-331-1833. E-mail: lchan@extro.ucc.su.oz.au. Objective: Recent studies suggest that the viral burden reached at the resolution of primary infection may determine disease outcome. Decreasing the viral burden at this early stage of disease is therefore of potential benefit. Greatest decreases in HIV viral burden have been reported using combinatio |
| Lb.B.6020 | Utilization of phototherapy and photochemotherapy (UV therapy) for treatment of skin conditions in HIV infection in the U.S. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. LB.B.6020) Beer JZ, Mills DK, Lightfoote MM, Zmudzka BZ, Krell K, Stern RS; Food and Drug Administration, Rockville, MD. Fax: (301) 594-6775. Objectives: To determine (a) ultraviolet radiation (UV) modalities used for treatment of skin conditions in HIV infection, (b) the indications for the use of such modalities, and C) HIV-disease stage of the UV-therapy patients (pts). Methods: During 2 two-week periods between late fall 1994 and early spring 1995, data |
| Lb.B.6019 | Antiretroviral activity and safety of indinavir (IDV) alone and in combination with zidovudine (ZDV) in ZDV-naive patients with CD4 cell counts of 50-500 cells/mm(3). Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. LB.B.6019) Berry P, Kahn J, Cooper R, Chung M, Meibohm A, Arcuri K, Massari F, Chodakewitz J; Merck Research Laboratories, West Point, PA. Fax: (610) 834-7555. Objectives: To compare the activity and safety of IDV 800 mg q8h vs. IDV+ZDV in ZDV- and protease inhibitor-naive patients with CD4 cell counts between 50-500 cells/mm(3). Methods: A prospectively planned preliminary analysis was done on the first 266 patients to be randomized in an ongoing double-blind surrogate marke |
| Lb.B.6018 | The role of the general practitioner in prevention of sexually transmitted infections in The Netherlands. Preliminary results of a peer-centered continuous education programme. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. LB.B.6018) van Bergen J; Dutch National Society of General Practitioners, Department of Quality Assurance and Continuous Education, Amsterdam, The Netherlands. Fax: 31-50-3182432. Introduction: In March 1994 a project was started in order to integrate continuing education for general practitioners (GP s) about HIV in regular continuing education in the Netherlands . The strategy was to create a network of regional GP s with additional knowledge and interest in the field of prevention and care of |
| Lb.B.6017 | Antiretroviral activity and safety of indinavir (IDV) alone and in combination with zidovudine (ZDV) in ZDV-naive patients with CD4 cell counts of 50-250 cells/mm(3). Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. LB.B.6017) Suleiman J, Lewi D, Uip D, Pedro R, Suleiman G, Accetturi C, Lima AL, Abreu W, Levi G, Teixeira P, Alencar R, Moraes-Filho JJ, Motti E, Pecoraro ML, Makurath M, Nessly M, Leavitt R; MSD Brazil, Sao Paulo, SP, Brazil. Fax: 55-11-212-6512. Objectives: To compare the activity and safety of IDV 800 mg q8h vs. ZDV 200 mg q8h vs. IDV+ZDV in ZDV- and protease inhibitor-naive patients with CD4 cell counts between 50 and 250 cells/mm(3). Methods: A prospectively planned preliminary analysis was done on the first 224 patients to be randomized in an ongoing doubl |
| Lb.A.6016 | Cell-mediated and humoral immune responses in HIV-1 seropositive subjects receiving the HIV-1 immunogen. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. LB.A.6016) Moss R, Trauger R, Wallace M, Turner J, Kim YB, Giermakowska W, Savary J, Richieri S, Daigle A, Ferre F, Jensen F, Carlo D; Immune Response Corporation, Carlsbad, CA. Fax: (619) 431-8636. E-mail: shotdoc@imnr.com. Cellular and humoral immune responses were measured in HIV-1 seropositive subjects receiving gp 120-depleted, inactivated HIV-1 antigen in Incomplete Freund s Adjuvant (HIV-1 Immunogen) during an open-labeled treatment study. Gamma interferon (INFgamma) levels were measurable in 8/13 (62%) subjects constitutively and i |
| Lb.A.6015 | T-20 and T-1052, novel inhibitors of HIV fusion, block infection of human macrophages by HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. LB.A.6015) Black P, Wood O, Bacho M, Lambert D, Guthrie K, Barney S, Ussery M; U.S.F.D.A., Rockville, MD. Fax: (301) 594-6289. E-mail: blackp@cder.fda.gov. Objective: To determine the antiviral activity of T-20 and T-1052, novel inhibitors of HIV fusion, in human macrophages. Method: Monocyte/macrophage (MM) cultures were derived from healthy adult human peripheral blood mononuclear cells (PBMC) by adherence to plastic and were maintained in culture with granulocyte-macro |
| Lb.A.6014 | Anti-HIV properties of Chinese medicinal herb-H.C.X. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. LB.A.6014) Zhou HC, Hudson JB, Lee W; Zhuollen Technology Ltd., New Westminster, BC, Canada. Fax: (604) 936-8806. Objective: To evaluate Chinese Herbal Complex X for anti-HIV activity. Materials: Lonicera japonica; Taraxacum monoglicum; Phellodendron Chinese; Coix lacryma-jobi; Astragalus membranaceus; Boswellia carterii, etc. Methods: The plaque-assays of evaluation of HCX had carried out in virology laboratory, Division of Medic |
| Lb.A.6013 | Immunogenic profile and efficacy testing in macaques immunized with an avipox/env(SF2) recombinant virus. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. LB.A.6013) De Giuli MC, Gimelli M, Ghioni C, Radaelli A, Teeuwsen V, van Gils M, den Haaft P, Borgers W, Heeney JL; University of Milan, Milan, Italy. Fax: 0039-2-7014637. E-mail: degiuli@imiucca.csi.unimi.it. Objective: To analyze the immune response of Rhesus macaques immunized with live, non replicating, recombinant Fowlpoxvirus carrying the complete HIV-1(SF2) env gene, and to verify its protective ability. Methods: On the genetic background of Fowlpoxvirus, a live, recombinant vector containing the HIV-1(SF2) env gene h |
| Lb.A.6012 | High level and stable HIV-1 resistance in CD4+ cells by multi-targeting antisense RNA incorporated into UI snRNA. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. LB.A.6012) Liu D, Donegan J, Kelker N, Nuovo G, Laurence J; Enzo Biochem, Inc., Farmingdale, NY. Fax: (212) 856-0878. E-mail: bet3@cornell.edu. Objective: To develop high level and stable resistance to HIV-1 in CD4+ cells as a critical step in the development of ex vivo antisense therapy. Methods: We have produced immune cells with stable and high level resistance to HIV-1 by the introduction of an antisense RNA-producing DNA construct. In order to overcome th |
| Lb.A.6011 | "Designer nucleases" with HIV-1 RNA specificity and their use in anti-HIV-1 gene therapy. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. LB.A.6011) Joshi S, Melekhovets YF; Department of Microbiology. University of Toronto, ON, Canada. Fax: (416) 638-1459. E-mail: sadhna.joshi.sukhwal@utoronto.ca. Objective: An alternative and novel class of molecules that could be used for anti-HIV-1 gene therapy would include designer nucleases that would specifically recognize and cleave HIV-1 RNAs. Such nucleases could be engineered by conferring TAR RNA specificity to an RNase so that they will specifically recognize and cl |
| Lb.A.6010 | Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. LB.A.6010) Chiu CP, Effros RB, Allsopp R, Hausner MA, Hirji K, Wang L, Harley CB, Villeponteau B, West MD, Giorgi JV; Geron Corporation, Menlo Park, CA. Fax: (415) 473-7750. E-mail: cchiu@geron.com. Objective: To test the hypothesis that the expanded population of non-proliferative CD28-CD8+ T cells in HIV disease have shortened telomeres, thereby providing evidence that increased rounds of CD8+ cell division occur during HIV disease, possibly leading to replicative senescence and exhaustion of CD8+ T cell respons |
| Lb.A.6009 | HIV-1 gene expression in members of the dendritic cell family depends upon their microenvironment. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no.f LB.A.6009) Tenner-Racz K, von Stemm A, Raschdorff B, Dietrich M, Racz P; Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg, Germany. Fax: 49 60 31182309. DCs from peripheral blood support HIV-1 replication in vitro but data concerning the in vivo role of these cells as targets for HIV-1 are controversial and it was therefore our aim to evaluate whether or not members of the dendritic cell (DC) family are productively infected by HIV-1. Methods: Surgical speci |
| Lb.A.6008 | HIV Tat represses HLA-G expression in human trophoblasts. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. LB.A.6008) Slabiak TM, Lim KH; UCSF, Department of OB/GYN & Reproductive Sciences, San Francisco, CA. Fax: (415) 753-3271. E-mail: GIRL_CLONE@UCSF.EDU. Objective: To determine the effect of HIV Tat protein on trophoblast HLA-G expression in vitro. Methods: Transient transfections were performed on JEG human choriocarcinoma cells which are known to express the HLA-G molecule. JEG cells are grown to 1x10(6) cells per 60 mm petri dish. We co-transfected 1,2, and 3 microg |
| Lb.A.6007 | Identification of an A3 family supermotif epitope in HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. LB.A.6007) Threlkeld SC, Kalams SA, Sette A, Johnson RP, Wilkes B, Ruhle D, Walker BD; MGH, Charlestown, MA. Fax: (617) 726-5411. E-mail: THRELKELDS@Al.mgh.harvard.edu. Objective: To define CTL epitopes in HIV-1 which can be presented by multiple alleles in the HLA A3 superfamily (HLA3, A11, A31, A68). Methods: Limiting dilution cloning of CD8 cells was performed in HIV-1 infected persons expressing either HLA A3 or A11. HIV-1 specific CTL clones restricted by HLA A3 and A11 were iden |
| Lb.A.6006 | Novel ribonuclease resistant RNA standards for HIV diagnostics. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. LB.A.6006) Pasloske B, DuBois D, Winkler M; Ambion, Inc., Austin, TX. Fax: (512) 445-7139. Introduction: Quantitative assays (PCR, bDNA, NASBA) for RNA viruses are rapidly increasing in use for both patient management and as markers for the efficacy of antiviral agents in clinical trials. These developments have created a need for well-defined RNA standards for calibrating individual assays for comparing dat |
| Lb.A.6005 | Comparison of branched chain DNA and RT-PCR for quantifying six different HIV-1 subtypes in plasma. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. LB.A.6005) Dunne AL, Crowe SM; Macfarlane Burnet Centre for Medical Research, Fairfield, Australia. Fax: 61 3 9482 6152. E-mail: tolli@burnet.mbcmr.unimelb.edu.au. Objective: To examine the ability of two commercially available assays to quantify HIV-1 RNA of different genomic subtypes in plasma. Design: The branched chain DNA assay (bDNA; Quintiplex HIV-1, Chiron Corporation, Emeryville, CA, USA) and the reverse transcriptase polymerase chain reaction assay (RT-PCR; Amplicor Mon |
| Lb.A.6004 | Identification of a molecular mechanism for HIV-1 Vpr-induced G2 cell cycle arrest. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. LB.A.6004) Takaori-Kondo A, de Noronha C, McEntee M, Greene W; Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA. Fax: (415) 826-15149826-1817. E-mail: akifumi_takaori-kondo.giv@quickmail.ucsf.edu. Objective: To delineate the molecular mechanism by which HIV-1 Vpr induces G2 cell cycle arrest. Methods and Results: To identify cellular proteins that might functionally associate with Vpr, a yeast-two hybrid screen was performed using Vpr as bait . One specific Vpr-interacting cellular protein corresponded to the re |
| Lb.A.6003 | Cyclophilin mediates early events in HIV-1 life cycle via interaction with a putative cyclophilin receptor. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. LB.A.6003) Zybarth G, Dubrovsky L, Bucala R, Ulrich P, Rich D, Cerami A, Sherry B, Bukrinsky M; The Picower Institute for Medical Research, Manhasset, NY. Fax: (516) 365-5090. To determine whether viral-associated cyclophilin facilitates HIV-1 entry or uncoating by interacting with a putative cyclophilin binding protein accessible on the surface of target cells. Methods: PBMCs and cell lines were infected with HIV-1 in the presence and absence of excess exogenously added cyclophil |
| Lb.A.6002 | Hematopoietic stem cell based gene therapy for AIDS. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. LB.A.6002) Junker U, Plavec I, Bonyhadi M, Baker J, Kaneshima H, Bohnlein E; Systemix, Inc., Palo Alto, CA. Previously, we and others have demonstrated the anti-HIV efficacy of a dominant-negative Rev mutant (RevM10) in T cell lines and primary T cells. We have further optimized retroviral vectors to maximize expression of the RevM10 gene measured by intracellular FACS analysis and could demonstrate a correlation between Rev |
This information is designed to support, not replace, the relationship that exists between you and your doctor.